1-3 of 3
Zhongliang Sun
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Time-Limited of Zanubrutinib, Rituximab and Lenalidomide (ZR2) Regimen for the Treatment of Super-Elderly Diffuse Large B-Cell Lymphoma (DLBCL): A Prospective, Exploratory Clinical Study

Jie Zou, Xiaoning Yu, Xiaoxia Chu, Ji Ma, Zengjun Li, Chunyan Chen, Yan Liu, Jian Xing, Zhongliang Sun, Chunyan Ji, Jie Li
Journal: Blood
Blood (2024) 144 (Supplement 1): 1732.
https://doi.org/10.1182/blood-2024-207021
Published: 2024
Journal Articles

Efficacy and Safety Analysis of Carfilzomib-Containing Regimen in the Treatment of Multiple Myeloma：a Multicenter Real-World Study

Na Liu, Luqun WANG, Rentong Liu, Yuping Zhong, Xianqi Feng, Zhongliang Sun, Jie Li, Fanjun Meng, Junjie MA, Changyong Yuan, Hao Li, Ling Wang, Zhilong Xu, Jie Yu, Hao Zhang, Chen Chunyan
Journal: Blood
Blood (2023) 142 (Supplement 1): 6632.
https://doi.org/10.1182/blood-2023-179687
Published: 2023
Journal Articles

Interim Report of Bendamustine Plus Rituximab As First-Line Induction Therapy with or without Lenalidomide Maintenance Therapy in Chinese Patients with Indolent Non-Hodgkin's Lymphoma or Elderly Mantle Cell Lymphoma: Data from a Multi-Center Prospective Trial

Hui Wang, Qiang He, Rongrong Zhao, Linna Xie, Ji Ma, Cong Liu, Ke Lu, Haichen Wei, Dan Liu, Lijie Xing, Xiuzhi Deng, Zhongliang Sun, Xiaoxia Chu, Na Gao, Yuping Zhong, Yanhua Sun, Haiyan Zhang, Hao Zhang, Wenwei Xu, Zengjun Li
Journal: Blood
Blood (2022) 140 (Supplement 1): 11962–11963.
https://doi.org/10.1182/blood-2022-162507
Published: 2022